Acquity ultra performance lc uplc system

Manufactured by Waters Corporation

Sourced in United States

The ACQUITY Ultra Performance LC (UPLC) System is a liquid chromatography instrument designed for high-performance separations. It utilizes sub-2-micron particle technology to achieve enhanced resolution, sensitivity, and speed compared to traditional HPLC systems.

Automatically generated - may contain errors

Lab products found in correlation

Masslynx nt software version 4, by Waters Corporation (2 mentions) Integral autoinjector, by Waters Corporation (2 mentions) Analyst 1, by AB Sciex (1 mentions) Triart c18 column, by YMC (1 mentions) Targetlynx applications manager version 4, by Waters Corporation (1 mentions) Sample manager, by Waters Corporation (1 mentions) Masslynx 4, by Waters Corporation (1 mentions) Xevo tq s mass spectrometry, by Waters Corporation (1 mentions) Acquity uplc hss c18 column, by Waters Corporation (1 mentions) Millex lg, by Merck Group (1 mentions) Photodiode array pda detector, by Waters Corporation (1 mentions) Xevo tandem quadrupole mass spectrometer, by Waters Corporation (1 mentions)

Close spelling variants of this product

Acquity UPLC system (1422 citations) Acquity UPLC (716 citations) UPLC system (190 citations) Acquity system (56 citations) Acquity LC system (12 citations) ACQUITY Ultra Performance system (2 citations)

7 protocols using acquity ultra performance lc uplc system

Quantification of S1P Levels in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fractionated plasma samples were mixed with an internal standard solution (100 ng/mL of pioglitazone), followed by deproteinization with 4 volumes of methanol and 4 volumes of acetonitrile. After centrifugation at 15,000 rpm for 5 min, deproteinized supernatants were evaporated using a Speed-Vac concentrator (Kubota, Tokyo, Japan), and the dried samples were dissolved in methanol. To quantify the S1P concentrations in each sample, LC/MS/MS multiple reaction monitoring analyses were conducted on a XEVO^TM Tandem Quadrupole Mass Spectrometer coupled to an ACQUITY Ultra Performance LC (UPLC) System with an integral autoinjector (Waters, Milford, MA, USA). The XEVO spectrometer was run in electrospray ionization-MS/MS multiple reaction monitoring mode at a source temperature of 120 °C and a desolvation temperature of 350 °C. The sample temperature was maintained at 4 °C and the column temperature was maintained at 50 °C. The mobile phases were 0.1% formic acid solution (solvent A) and liquid chromatography-grade acetonitrile (Sigma Aldrich, Inc., St Louis, MO, USA) (solvent B). The UPLC and mass spectrometer conditions are shown in Supplementary Table S1.
Data analyses were performed using MassLynxNT software version 4.1 (Waters).

Yamanashi Y., Takada T., Yamamoto H, & Suzuki H. (2020). NPC1L1 Facilitates Sphingomyelin Absorption and Regulates Diet-Induced Production of VLDL/LDL-associated S1P. Nutrients, 12(9), 2641.

+ Open protocol

+ Expand

Metabolite Profiling by LC-ESI-MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Each of the separated fractions by HPLC was subjected to an LC-ESI-MS analysis using a SQD single quadrupole mass spectrometer (Waters) equipped with the ACQUITY ultraperformance LC (UPLC) system (Waters). The sample injection volumes of 5 μl each were separated on Develosil HB C30-UG (2.0 mm × 100 mm, Nomura) at the flow rate of 0.3 ml/min. A gradient of solvent A (water) with solvent B (acetonitrile) was used as follows: 5% B at 0 min, 95% B at 8 min, and 95% B at 13 min. The MS scan was performed in the positive ion mode using nitrogen as the nebulizing gas. The experimental conditions were as follows: ion source temperature, 120 °C; desolvation temperature, 350 °C; cone voltage, 20 eV; desolvation gas flow rate, 800 l/h.

Yamaguchi K., Itakura M., Tsukamoto M., Lim S.Y, & Uchida K. (2022). Natural polyphenols convert proteins into histone-binding ligands. The Journal of Biological Chemistry, 298(11), 102529.

+ Open protocol

+ Expand

FMISO Metabolite Quantification by LC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

To obtain product ion spectra and determine concentrations of FMISO and its metabolites, tumour homogenates were injected into the LC-MS/MS system. An Acquity ultra-performance LC (UPLC) system (Waters Co., Milford, MA, USA) with a triple quadrupole mass spectrometer (API 5000™, AB Sciex, Foster City, CA, USA) was used for LC-MS/MS analysis. The LC-MS/MS system was controlled by Analyst 1.4.2 (AB Sciex) software. Chromatographic separation was performed using a YMC-Triart C18 column (50 × 2 mm, 1.7 μm, YMC Co., Ltd., Kyoto, Japan) at 25 °C. Separation was achieved by gradient elution with mobile phase composed of 15 mM ammonium hydrogen carbonate (A) and acetonitrile (B). The analytes were eluted by a 1–95% B linear gradient. The total UPLC run times were 20 and 3 min, at flow rates of 0.2 and 0.5 ml/min for obtaining product ion spectra and determining concentrations, respectively. The autosampler compartment temperature was 4 °C. ESI was performed in the positive-ion mode.

Masaki Y., Shimizu Y., Yoshioka T., Tanaka Y., Nishijima K.I., Zhao S., Higashino K., Sakamoto S., Numata Y., Yamaguchi Y., Tamaki N, & Kuge Y. (2015). The accumulation mechanism of the hypoxia imaging probe “FMISO” by imaging mass spectrometry: possible involvement of low-molecular metabolites. Scientific Reports, 5, 16802.

+ Open protocol

+ Expand

Quantitative Analysis of Hepatic Bile Acids

Check if the same lab product or an alternative is used in the 5 most similar protocols

Quantitative analysis of hepatic bile acids was measured following published methods with modifications (García-Cañaveras et al., 2012 (link); Xie et al., 2013 (link); Xie et al., 2015 (link)). Mouse liver homogenate samples or standard solutions were mixed with acetonitrile (1:3, v/v) containing internal standards, then the extractions were centrifuged and the supernatants were combined and dried. The dried residues were resuspended in acetonitrile/methanol (95:5, v/v) and centrifuged at 13,500 g at 4°C for 20 min for further solid-phase extraction. The supernatant was transferred to a 96-well plate for LC-MS analysis. A Waters ACQUITY ultra performance LC (UPLC) system equipped with a binary solvent delivery manager and a sample manager (Waters, Milford, MA) was used throughout the study. UPLC-MS raw data obtained with negative mode were analyzed using TargetLynx applications manager version 4.1 (Waters Corp., Milford, MA) to obtain calibration equations and the quantitative concentration of each bile acid in the samples. Total hepatic bile acids were calculated from the sum of individual bile acid species and normalized to tissue weight.

Chen L., Wang Y., Zheng W., Zhang H., Sun Y., Chen Y, & Liu Q. (2023). Improvement of obesity-induced fatty liver disease by intermittent hypoxia exposure in a murine model. Frontiers in Pharmacology, 14, 1097641.

+ Open protocol

+ Expand

Liver Metabolomics and Lipid Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The liver samples were harvested and underwent targeted metabolomics profiling analysis. Firstly, Q300 Kit (Metabo-Profile, Shanghai, China) was used to generate all raw metabolites data by UPLC-MS/ MS. Then data was processed at iMAP platform. For another, lipid profiling of liver was also generated on a Waters ACQUITY Ultra-Performance LC (UPLC) system. A Waters XEVO TQ-S mass spectrometry and MassLynx 4.1 software (Waters, Milford, MA) were also used to generate and process data. At first, distribution characteristics of metabolite profile between groups was identified by Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis. According to the OPLS-DA model, VIP (variable importance in projection) was obtained and was used for following process. Metabolites with p-value < 0.05 and VIP ≥ 1 were screened as statistically significant metabolites. Following analysis of enriched pathway was performed with selected metabolites.

Cai L.Q., Li X.C., Wang Y.Y., Chen Y.X., Zhu X.Y., Zuo Z.Y., Si-Ma Y.Q., Lin Y.N., Li X.K, & Huang X.Y. (2024). Investigation of Metabolic and Inflammatory Disorder in the Aging FGF21 Knockout Mouse. Inflammation.

+ Open protocol

+ Expand

UPLC-UV Analysis for Sildenafil Identification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Forty-nine milligrams of the sample was accurately weighed and solved in 5 mL of methanol. Extraction was carried out by the ultrasonication and shaking, each for 15 min. The mixture was centrifuged at 1,710×g for 10 min, and then the supernatant was passed through a 0.2-μm filter (Millex LG; Merck Millipore Corporation, Billerica, MA, USA) to obtain a tested solution. Sildenafil and descarbonsildenafil standards were dissolved in methanol. Where necessary, the tested solution was diluted with methanol to obtain an adequate concentration before analysis. LC-UV was conducted on an AC-QUITY ultra-performance LC (UPLC) system with a photodiode array (PDA) detector (Waters Division, Wa- ters Corporation, Milford, MA, USA), using an ACQUI-TY UPLC HSS C18 column (2.1×150 mm i.d., particle size 1.8 μm) (Waters) at 50℃. LC-UV analysis was car- ried out with a binary mobile phase consisting of solvent A [acetonitrile/water/phosphoric acid (100 : 900 : 1, v/v/v) containing 5 mM sodium 1-hexanesulfonate] and solvent B [acetonitrile/water/phosphoric acid (900 : 100 : 1, v/v/v) containing 5 mM sodium 1-hexanesulfonate]. The flow rate was 0.4 mL/min. The linear gradient program was as follows: 0-0.5 min, 8.5％ B; 0.5-10.0 min, 8.5-94.7％ B; and 10.0-12.25 min, hold at 94.7％ B. The scan range of the PDA detector was 210-400 nm.

Ichikawa-Kaji Y., Nakajima J., Kikkawa S., Ishizawa F., Nishiyama R., Kishimoto K., Uemura N., Satoh M., Suzuki J., Inomata A., Nakae D., Azumaya I., Honda K, & Moriyasu T. (2020). [Identification of Descarbonsildenafil in an Adulterated Dietary Supplement and Evaluation of Its Inhibitory Activity for Phosphodiesterase Type 5 (PDE5)]. Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan, 61(1).

+ Open protocol

+ Expand

Quantitative Lipoprotein Drug Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

LC/MS/MS multiple reaction monitoring analyses were conducted on a XEVO™ Tandem Quadrupole Mass Spectrometer coupled to an ACQUITY Ultra Performance LC (UPLC) System with an integral autoinjector (Waters, Milford, MA). The XEVO spectrometer was run in electrospray ionization-MS/MS multiple reaction monitoring mode at a source temperature of 120 °C and a desolvation temperature of 350 °C. Sample temperature was kept at 4 °C, and column temperature was kept at 50 °C. The mobile phases were 0.1% formic acid solution (solvent A) and liquid chromatography-grade acetonitrile (Sigma Aldrich, Inc., St Louis, MO) (solvent B). The UPLC conditions and mass spectrometer conditions are shown in Supplementary Table S2. Data analyses were performed using MassLynxNT software (version 4.1) (Waters).
Drug association with lipoproteins and albumin was calculated by dividing the drug content in the lipoprotein or albumin fraction by the injected serum drug content. The free fraction was obtained from the DrugBank database^{30 (link)}. In cases in which the sum of the drug association with lipoprotein, albumin, and free fractions was more or less than 100%, the sum of each association rate was adjusted to 100%.

Yamamoto H., Takada T., Yamanashi Y., Ogura M., Masuo Y., Harada-Shiba M, & Suzuki H. (2017). VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. Scientific Reports, 7, 633.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!